Twitter Facebook LinkedIn

News & Events

June 17, 2022 | Merck – SMART Surveillance

SMART Surveillance
Conducted by Merck

Access Information:

To access Merck’s SMART Surveillance program, submit a request for the SMART datasets to be redirected to the appropriate Merck website:

  • SMART Surveillance Heatmaps
  • SMART Surveillance data request

Primary objective
Global surveillance; resistance trend analysis; fulfilment of regulatory commitments.

 

Protocol SummarySpecimens are collected, as per hospital protocol, from patients suspected with having an infectious disease and sent to the microbiology lab for identification, and susceptibility testing, of the suspected pathogen.
Each site enrolled in SMART collects 50 clinical gram-negative (GN) isolates from IAI, UTI and BSI; 100 GN isolates from RTI. Only the first isolate per patient is collected.
The isolates are sent to the SMART surveillance program central lab (IHMA) for confirmation of identification and susceptibility testing.
Participating labs indicate on form whether isolate was collected =<48h prior to admission to the hospital or >48h after admission. In addition age and hospital location is indicated.
Subsequently, isolates that conform to a molecular algorithm are tested for mechanisms of resistance.
Number of Isolates300,000+
Contains pediatric data?Yes
Contains genotype data?Yes
Date Last UpdatedThru Dec-2020
Expected frequency of updates to the datasetAnnually
Publications Register and log in at globalsmartsite.com then navigate to Resources and Publications globalsmartsite.com/#/resources/publications